SHARE NOW
With Advanced Therapies Week (ATW) 2025 just a couple of months away, we want to celebrate the event’s home for the year: the thriving city of Dallas, Texas.
Texas has a thriving life science industry and is fast becoming a biotech hub. Take Pegasus Park’s biotech+ and life sciences hub in Dallas. Pegasus Park features accelerator programs that help biotech and life science startups scale into high-growth companies.
BioLabs Pegasus Park provides biotech startups with everything they need to launch into high-growth companies, including 37,000 square feet of lab, training, and office space, mentoring, networking, and proximity to other innovators.
Many leading cell and gene therapy biotechs have headquarters in Dallas, Houston, Austin, and other locations in the state. We’ve put together a list of Texas biotech companies focused on cell and gene therapy. This includes two companies headquartered just a 10-minute drive from the Kay Bailey Convention Center, which is where ATW 25 is taking place. The companies are arranged alphabetically below.
Cellenkos
Cellenkos, which is based in Houston, Texas, is a clinical stage biotech cell therapy company focused on treating autoimmune diseases and inflammatory disorders.
In early 2024, the company was given the given the green light to treat a second group of patients in its REGALS trial following the publication of encouraging safety data. The trial aims to establish safety and tolerability of multiple doses of CK0803 neurotrophic T regulatory cell therapy in patients with Amyotrophic Lateral Sclerosis.
Celling Biosciences
Celling Biosciences is only one of the Texas biotech companies on this list based in Austin, Texas. It develops point-of-care, autologous regenerative cell therapies through its surgical techniques and technology platform.
In July 2024, the company introduced its Cell Probe 360 technology to the market. This is a new take on an aspiration needle for enhancing the method of bone marrow collection.
Celltex
Celltex is focused on breakthroughs using autologous, adipose-derived Mesenchymal Stem Cells (MSCs). The Houston, Texas-based biotech company has a number of ongoing clinical trials.
These trials include a Phase 1/2a clinical trial utilizing autologous MSCs for rheumatoid arthritis and a Phase 2 clinical trial utilizing autologous MSCs for osteoarthritis.
Coya Therapeutics
Coya Therapeutics is one of the many Texas biotech companies based in Houston, Texas. This clinical stage biotechnology company is developing modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
The company recently announced the results of its double-blind study of subcutaneous low-dose interleukin-2 (LD IL-2) in Alzheimer’s disease. The study successfully met its primary and secondary endpoints, demonstrating that treatment with LD IL-2 is safe and well-tolerated in patients with AD.
Gradalis
Gradalis is based in Carrollton, Texas and is a clinical-stage biotechnology company developing personalized anti-cancer therapies.
At the end of 2023, the Cancer Prevention and Research Institute of Texas awarded Gradalis a $9.9 million Product Development Research grant. This will support Gradalis’s Phase 2 clinical study of its Vigil personalized, patient-specific cancer immunotherapy in platinum-sensitive patients who have recurrent ovarian cancer.
InGeneron
InGeneron is a clinical-stage biotechnology company developing cell-based therapies to redefine the standard of care in orthopedics. The company’s headquarters are located near the Houston medical center.
Recent updates from the company include the news that its randomized controlled trial treating partial-thickness rotator cuff tears met primary endpoint and finds statistically significant durable patient benefit 3.4 years post-treatment.
Kiromic Biopharma
Kiromic Biopharma is a Gamma Delta T-cell (GDT) company based in Houston, Texas. It develops bioinformatic, AI-targeting, and manufacturing technologies to treat solid tumors.
The Texas biotech company’s ongoing Deltacel-01 Phase 1 clinical trial is evaluating a drug called Deltacel (KB-GDT-01) in patients with stage 4 metastatic non-small cell lung cancer who have failed to respond to standard therapies. Deltacel is the company’s allogeneic, off-the-shelf, GDT therapy.
It recently provided an update on the clinical results from the trial so far, with the median progression-free survival now at six months.
Nanoscope Therapeutics
Nanoscape Therapeutics is based just a 10-minute drive away from the Kay Bailey Convention Center – the location for ATW 2025 – in Dallas. This Texas biotech is developing gene therapies for retinal degenerative diseases and age-related macular degeneration.
The company’s Phase 3 registrational trial will be the first randomized, controlled gene therapy trial for Stargardt Macular Degeneration disease and is expected to commence in the near-term.
Taysha Gene Therapies
Another company headquartered just a 10-minute drive from the ATW 25 convention center, Taysha Gene Therapies lives and breathes Texas. The word “Taysha” means “ally” or “friend” in the Caddo Native American language and when translated, also means “Texas”.
Taysha Gene Therapies focuses on advancing adeno-associated virus-based gene therapies for severe monogenic diseases of the central nervous system.
The Texas biotech recently positive longer-term clinical data from its ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data from the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome. Initial data from first two pediatric patients showed improvements across multiple efficacy measures and clinical domains, with early evidence of developmental gains
Connect with Texas Biotech Companies at ATW 2025
Advanced Therapies Week 2025 is taking place 20-23 January 2025 at the Kay Bailey Convention Center. If you’d like to connect with Texas biotech companies, or if you are a biotech interested in attending, take a look at the agenda, speakers, and different types of tickets on offer.
